Search

The article provides information on a study presented by medical student Rashad Rahman at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting which showed that caveolin-1 (CAV1) and Rho-associated kinase 1 (ROCK1) were consistently associated following mechanical stress, which may affect cellular contractility. Topics discussed include CAV1 study design, major study findings, and importance of studying changes in the CAV1 interactome.

The article discusses as the global population continues to rise, the United Nation expects it to reach 9.8 billion by 2050. It mentions to achieve environmental and climate change goals, food to meet this demand will have to be produced sustainably; and also mentions that extrusion is used to produce the main ingredient used in plant-based meat production, textured vegetable protein (TVP).

The article focuses on the challenges associated with bone repair using traditional methods like autografts and allografts, highlighting limitations such as immune system rejections and morbidity issues. It discusses the potential of additive manufacturing techniques, specifically 3D printing, in creating scaffolds with optimal properties for bone tissue regeneration, emphasizing the need for interconnected porous structures and the challenges of using hybrid materials.

The article discusses a research and development study for chemically synthesizing a synthetic retina of the eye. Topics discussed include the way retina enables vision, details on the retina membrane and proteins that can be used to detect light. Topics including designing the scaffold, details on building of the retina and its modifications are also discussed.

The article reveals that Vicente A. Diaz, an assistant professor of clinical ophthalmology at Yale School of Medicine in New Haven, Connecticut, points out that Biovance 3L Ocular (Celularity), a novel amniotic membrane product, seems highly promising for its role in ocular regenerative procedures. Topics discussed include study conducted to evaluate the performance of Biovance 3L, and information on pterygia.

The article reports that researchers are developing polymer scaffolds that can be implanted in the body to support the growth of new tissue and mentions that propylenefumarate (PPF) is material available for tissue engineering.

The article reports on investigational therapies based on fibronectin-integrin interactions for the treatment of non-healing corneal epithelial defects that are refractory-to-conventional management techniques, according to Doctor Teuro Nishida. Topics discussed include autologous fibronectin eyedrops, eyedrops formulated with a fibronectin-derived peptides, and peptides derived from substance P plus insulin-like growth factor-1 (IGF-1).

The article reports that a team of engineers has successfully created a superstretchy hydrogel with record toughness. It mentions that the new material could help improve the performance of products made from hydrogels including flexible contact lenses and tissue engineering scaffolds. It also informs that it will open up applications for which hydrogels can be used in materials for cartilage replacement.

The article reports on the study conducted by investigators at the Lawrence Berkeley National Laboratory (LBL) and Imperial College London which uses the 6P53B bioactive glass material and the robocasting processing technique in producing scaffolds for bone replacement and regeneration. The researchers reveal their progress in making scaffolds with compressive strength of about 136 megapascals. It is noted that the strength of the porous glass scaffolds is 100-times that of polymer scaffolds.

The article offers information on the development of a kinase enzyme inhibitor which may be used in the treatment of melanoma. Researchers from Plexxikon discovered the drug candidate PLX4-32 by screening for small scaffolds that has a weak bond with the kinase B-Raf, which causes metastatic melanoma and whose mutation can be found in about half of all types of melanomas. A potential B-Raf inhibitor was developed from the scaffold core.